Advocates Descend Upon Annual Meeting of the CND in Vienna

This week the United Nations (UN) Committee on Narcotic Drugs (CND) has their annual meetings in Vienna. The CND is responsible for implementing international drug control treaties as well as the scheduling of drugs. The CND makes decisions about scheduling new substances as well as changing the scheduling. The CND base these decisions on recommendations from the World Health Organization (WHO). The WHO makes their recommendations on the scheduling of drugs only after the Expert Committee on Drug Dependence (ECDD) prepares a critical review document.

Today’s agenda for the CND delegation includes the “Implementation of the international drug control treaties,” where they will discuss “changes in the scope of controlled substances” and “international cooperation to ensure the availability of narcotic drugs and psychotropic substances for medical and scientific purposes while preventing their diversion.”

It is not clear which substances they will be discussing. However, the UN is following WHO’s recommendation and will not be voting on CBD’s international scheduling status. In December 2017, the ECDD released a critical review document on CBD that stated, “in its pure state, cannabidiol does not appear to have abuse potential or cause harm” and recommended to the UN that it remain out of the scheduling scheme all together.

Cannabis, including medical cannabis and its resin, is currently classified as Schedule I in the U.S. and IV under the UN Single Convention. This scheduling was determined based on a report created by the Health Committee of the League of Nations in 1935. The ECDD is currently working on 4 critical review documents on cannabis that will be discussed at the 40th Expert Committee on Drug Dependence (ECDD) June 4-8, 2018 at the WHO Headquarters in Geneva. This is a special session on cannabis that will include the following “pre-reviews:”

• Cannabis plant and cannabis resin
• Extracts and tinctures of cannabis
• Delta-9-tetrahydrocannabinol (THC)
• Isomers of THC

The outcome of these reports will be presented by the WHO to the CND in future meetings. The CND is made up 53 member states (see breakdown below). Currently 22 CND delegations are from countries with medical cannabis laws.

(a) Eleven for African States*	(b) Eleven for Asian States*	(c) Ten for Latin American and Caribbean States*	(d) Six for Eastern European States	(e) Fourteen for Western European and other States
Algeria	Afghanistan	Argentina	Belarus	Australia
Burkina Faso	China	Brazil	Croatia	Austria
Cameroon	India	Chile	Czech Republic	Belgium
Côte d’Ivoire	Israel	Colombia	Kyrgystan	Canada
Democratic Republic of Congo	Iran	Cuba	Russian Federation	France
Kenya	Iraq	Ecuador	Slovakia	Germany
Mauritania	Japan	El Salvador		Hungary
South Africa	Pakistan	Guatemala		Italy
Sudan	Qatar	Mexico		Netherlands
Togo	Republic of Korea	Peru		Norway
Uganda	Thailand	Uruguay		Spain
				Switzerland
				Turkey
				United States

Breakdown of Committee on Narcotic Drugs. Countries in blue have national medical cannabis laws, green have pending laws, and nations that are not highlighted do not have a functioning national medical cannabis program.

 *One seat to rotate between the Asian, and the Latin American and Caribbean States every four years